Loading clinical trials...
Loading clinical trials...
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more
NCT05278208 · High Grade Glioma, Meningioma, and more
NCT05651828 · Advanced Basal Cell Carcinoma
NCT07144384 · Skin Basal Cell Carcinoma, Skin Nodular Basal Cell Carcinoma, and more
University of Pittsburgh Medical Center SC
Pittsburgh, Pennsylvania
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5)
San Antonio, Texas
Novartis Investigative Site
Barcelona, Catalonia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions